{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.563"},{"groupId":"OG001","value":"0.473"},{"groupId":"OG002","value":"0.706"},{"groupId":"OG003","value":"0.739"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"23"}],"units":"Participants"}],"description":"Adverse events (AEs) were graded per CTCAEv5 and the worst grade experienced per participant was recorded. The Grade 3-5 toxicity rate is defined as the proportion of treated participants whose worst grade AE was Grade 3, 4, or 5 at any point during the observation period, regardless of treatment attribution.","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation\n\nStandard Chemotherapy: Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab\n\nDurvalumab: Durvalumab 1500 milligrams (mg) intravenous (IV) every 3 weeks + Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks for 4 to 6 cycles, followed by maintenance with Durvalumab 1500 mg IV every 4 weeks","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.\n\nIpilimumab and Nivolumab: Ipilimumab 1 mg/kg every 6 weeks and Nivolumab 360 mg every 3 weeks or 3 mg/kg every 2 weeks for up to 2 years","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"NUMBER","populationDescription":"The analysis population is comprised of treated patients.","reportingStatus":"POSTED","timeFrame":"AEs were recorded from randomisation until 30 days after last chemotherapy dose or 90 days after last durvalumab, ipilimumab, or nivolumab dose, whichever was longer. The treatment duration ranged from 0 to 36 months.","title":"Grade 3-5 Worst Degree Toxicity Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}